ASX Announcements


 
    Optiscan Receives Ethical Clearance for Breast Cancer Study  
 
    Optiscan 2024 Roadshow Presentation  
 
    Optiscan Reveals InVue Imaging Device for Precision Surgery  
 
    Optiscan Webinar Investor Presentation  
 
    Optiscan Webinar Following Mayo Clinic Agreement  
 
    Optiscan Signs Know-How Agreement with Mayo Clinic  
 
    OIL March 2024 Quarterly Report and Appendix 4C  
 
    Change in substantial holding  
 
    Optiscan appoints US Clinical & Regulatory Heads  
 
    Optiscan receives R&D Tax Incentive Rebate  
 
    OIL Appendix 4D and 31 December 2023 Half-year report  
 
    Optiscan receives $3 million CRC-P Industry Grant  
 
    OIL December 2023 Quarterly Report and Appendix 4C  
 
    Change of Company Auditor  
 
    Results of Annual General Meeting  
 
    OIL Managing Director's Presentation & Chair's Address  
 
    Response to ASX Price Query  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    OIL September 2023 Quarterly Report and Appendix 4C  
 
    Notice of Annual General Meeting/Proxy Form  
 
    2023 AGM - Letter to Shareholders & Proxy Form  
 
    Optiscan Announces Chief Operating Officer Appointment  
 
    Optiscan announces key appointments for US operation  
 
    Annual General Meeting Date  
 
    Optiscan Correlates with Histology in Breast Study  
 
    Appendix 4G & Corporate Governance Statement  
 
    OIL Appendix 4E and June 2023 Annual Report  
 
    Optiscan Achieves Telepathology Milestone  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Application for quotation of securities - OIL  
 
    Change of Director's Interest Notice  
 
    OIL June 2023 Quarterly Report and Appendix 4C  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change of Director's Interest Notices x3  
 
    Application for quotation of securities - OIL  
 
    Notification of cessation of securities - OIL  
 
    Entitlement Offer Results and Shortfall Announcement  
 
    Optiscan to present at key international congress in July  
 
    Update - Proposed issue of securities - OIL  
 
    Entitlement Offer Extension to Closing Date  
 
    Entitlement Offer - Letter to Ineligible Shareholders  
 
    Entitlement Offer documents despatched to Shareholders  
 
    Entitlement Offer Timetable Update  
 
    Proposed issue of securities - OIL  
 
    Optiscan Entitlement Issue Prospectus  
 
    Optiscan Launches Entitlement Offer to Raise $16.7M  
 
    Trading Halt  
 
    Optiscan Oral Study Published in Prestigious Medical Journal  
 
    OIL March 2023 Quarterly Report and Appendix 4C  
 
    Change of Director's Interest Notice  
 
    Notification of cessation of securities - OIL  
 
    Optiscan Establishes US Commercial Operation in Minnesota  
 
    Change of Director's Interest Notice - K Borg  
 
    Change of Director's Interest Notice - R Cooke  
 
    Optiscan Platform Highly Accurate for Oral Cancer Diagnosis  
 
    Optiscan Intends to pursue De Novo Pathway for InVivage  
 
    OIL Appendix 4D and 31 December 2022 Half-year report  
 
    Optiscan partners with Prolucid to develop AI Algorithms  
 
    OIL December 2022 Quarterly Report and Appendix 4C  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Results of Annual General Meeting  
 
    Optiscan Managing Director 2022 AGM Presentation  
 
    Optiscan Chairman's AGM Address  
 
    Statement pursuant to Listing Rule 4.7C.3  
 
    OIL September 2022 Quarterly Report and Appendix 4C  
 
    2022 AGM - Letter to Shareholders & Proxy Form  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Proposed issue of securities - OIL  
 
    Optiscan Imaging Acquires Intellectual Property  
 
    Optiscan receives R&D tax incentive rebate  
 
    Annual General Meeting Date  
 
    Appendix 4G & Corporate Governance Statement  
 
    Appendix 4E and 2022 Annual Report  
 
    Optiscan Submits FDA 510(k) Application for InVivage Device  
 
    OIL June 2022 Quarterly Report and Appendix 4C  
 
    Change in substantial holding  
 
    Notification of cessation of securities - OIL  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Strategic Distribution Partnership - Additional Information  
 
    Optiscan announces Strategic Distribution Partner for China  
 
    Optiscan to present at Head & Neck Cancer World Congress  
 
    Initial Director's Interest Notice  
 
    Appointment of Non-executive Director  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    OIL March 2022 Quarterly Report and Appendix 4C  
 
    Optiscan appoints key management staff  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice  
 
    Notification regarding unquoted securities - OIL  
 
    Notification regarding unquoted securities - OIL  
 
    Appendix 4D and 31 December 2021 Half-year report  
 
    OIL December 2021 Quarterly Report and Appendix 4C  
 
    Results of Annual General Meeting  
 
    Final Director's Interest Notice  
 
    2021 AGM Chairman's Address and MD Presentation  
 
    Notice of Annual General Meeting/Proxy Form  
 
    2021 AGM Letter to Shareholders and Proxy Form  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Final Director's Interest Notice  
 
    Change of Managing Director  
 
    Completion of imaging for Melbourne Breast cancer trial  
 
    Jobkeeper Payments Notice  
 
    Update to Annual General Meeting Date  
 
    OIL September 2021 Quarterly Report and Appendix 4C  
 
    Receipt of R&D Tax Incentive Rebate  
 
    Annual General Meeting Date  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Application for quotation of securities - OIL  
 
    Application for quotation of securities - OIL  
 
    Appendix 4G and Corporate Governance Statement  
 
    OIL FY21 Annual Results Presentation  
 
    Appendix 4E and 2021 Annual Report  
 
    Change of Director's Interest Notice  
 
    Notification regarding unquoted securities - OIL  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Final Director's Interest Notice  
 
    OIL June 2021 Quarterly Report and Appendix 4C  
 
    Initial Director's Interest Notice  
 
    Proposed issue of securities - OIL  
 
    Appointment and Resignation of Independent Director  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Section 708A Cleansing Notice  
 
    Application for quotation of securities - OIL  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    Update on seeking United States FDA approval & market entry  
 
    Change in substantial holding  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    Change of Director's Interest Notice  
 
    Appendix 3G  
 
    Appointment of new Non-executive Director  
 
    OIL March 2021 Quarterly Report and Appendix 4C  
 
    Initial Director's Interest Notice  
 
    Appointment of New Non-executive Chair  
 
    Change of Director's Interest Notices x2  
 
    Exercise of options by Directors & Appendix 2A  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    Appendix 4D and Financial Statements - 31 December 2020  
 
    Appointment of new Non-executive Director  
 
    OIL breast cancer study to commence next stage - revised  
 
    Optiscan breast cancer study to commence next stage  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    OIL December 2020 Quarterly Report and Appendix 4C  
 
    Carl Zeiss Meditec AG Product Orders  
 
    Appointment of Taiwan Distributor  
 
    Appendix 3G - issue of options  
 
    Appendix 3G - issue of options  
 
    Results of Annual General Meeting  
 
    OIL 2020 AGM Presentation  
 
    Annual General Meeting Resolution Withdrawal  
 
    TGA Approval for CONVIVO and Sterile Sheath In Australia  
 
    OIL September 2020 Quarterly Report and Appendix 4C  
 
    Presentation at Australia Biotech Invest & Partnering 2020  
 
    Notice of Annual General Meeting/Proxy Form  
 
    2020 AGM Letter to Shareholders and Proxy Form  
 
    US FDA Regulatory Approval update  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    Annual General Meeting Date  
 
    Section 708A Cleansing Notice and Appendix 2A  
 
    Receipt of R&D Tax Incentive Rebate  
 
    OptiScan Capital Raising  
 
    Proposed issue of Securities - OIL  
 
    Optiscan Capital Raising  
 
    Trading Halt  
 
    Pause in Trading  
 
    Response to ASX Price Query  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and 2020 Annual Report  
 
    New North American & Expanded Asia Pacific Distribution  
 
    Optiscan Investor Presentation  
 
    OIL June 2020 Quarterly Report and Appendix 4C  
 
    2 X China Tender Success for FIVE2 (ViewnVivo)  
 
    Optiscan Presentation  
 
    Government grant to support Melbourne Dental School Trial  
 
    Optiscan Presentation  
 
    Achievement of Final Milestone in Carl Zeiss Agreement  
 
    Amended Securities Trading Policy  
 
    OIL March 2020 Quarterly Report and Appendix 4C  
 
    Response to ASX Price Query  
 
    Pause in Trading  
 
    Corporate Update  
 
    Appendix 4D and Financial Statements - 31 December 2019  
 
    OIL Wholesale Investor Presentation - February 2020  
 
    Corporate Update - January 2020  
 
    Change of Director's Interest Notices x3  
 
    Section 708A Notice and Appendix 3B  
 
    Appointment of Second China Distributor  
 
    Results of Annual General Meeting  
 
    2019 AGM Presentation  
 
    Optiscan Market Update  
 
    Optiscan to Hold Investor Presentation in Perth  
 
    OIL initiates FDA feedback for Oral Cancer 510(k) submission  
 
    Optiscan Presentation at AusBiotech Conference  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Appointment of new China Distributor  
 
    Receipt of R&D Tax Incentive Rebate  
 
    Leading Aus & US Hospital Collaboration to trial OIL device  
 
    Change of Director's Interest Notice - G Mutton  
 
    Presentation at World Federation for Utrasound Conference  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and 2019 Annual Report  
 
    Amended Securities Trading Policy  
 
    Optiscan System Approved for Prestigious Cancer Centre Trial  
 
    Section 708A Notice and Appendix 3B  
 
    Investor Presentation - June 2019  
 
    Optiscan Secures Strong Support in $1.70 M Capital Raising  
 
    Trading Halt  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Investor Presentation - April 2019  
 
    OptiScan March 2019 Presentation (Amended)  
 
    OptiScan March 2019 Presentation  
 
    Appendix 4D and Financial Statements - 31 Dec 2018  
 
    Collaboration Agreement with Summit Biomedical Imaging LLC  
 
    OptiScan technology used in research at major cancer centre  
 
    Change of Director's Interest Notices x3  
 
    Appendix 3B  
 
    Results of Annual General Meeting  
 
    AGM Presentation  
 
    Optiscan to Hold Investor Presentation in Perth  
 
    Management Update  
 
    Receipt of R&D Tax Incentive Rebate  
 
    Reinstatement to Official Quotation  
 
    ZEISS achieves another milestone on regulatory pathway  
 
    Suspension from Official Quotation  
 
    Trading Halt Request  
 
    Trading Halt  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Clinical Trial - Assessment of Breast Cancer Margin  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and 2018 Annual Report  
 
    Appendix 3B  
 
    Receipt of R&D Tax Incentive Rebate  
 
    Market Update  
 
    Appendix 3B  
 
    ZEISS CONVIVO and Appointment of Interim Executive Chairman  
 
    Change of Director's Interest Notice - Graeme Mutton  
 
    Ceasing to be a substantial holder  
 
    Final Director's Interest Notice  
 
    Results of General Meeting  
 
    Appointment of Chairman & General Meeting Update  
 
    Initial Director's Interest Notice - Graeme Mutton  
 
    Initial Director's Interest Notice - Darren Lurie  
 
    Final Director's Interest Notice - Ian Griffiths  
 
    Final Director's Interest Notice - Peter Francis  
 
    Withdrawal of Senior Management Team Resignations  
 
    Final Director's Interest Notice - Alan Hoffman  
 
    Resignation and Appointment of Non-Executive Directors  
 
    Resignation of Director  
 
    Successful European conference participation  
 
    Notice of General Meeting/Proxy Form  
 
    Q&A with Executive Chairman - Alan Hoffman  
 
    Shareholder requisitions and forthcoming management changes  
 
    Notice of initial substantial shareholder  
 
    Receipt of Shareholder requisition notice  
 
    Notice of initial substantial shareholder  
 
    Receipt of Shareholder requisition notice  
 
    Optiscan Mid-Year Results  
 
    Appendix 4D and Financial Statements - 31 Dec 2017  
 
    Update on CEO Recruitment and Interim Management  
 
    Appendix 3B  
 
    Market Update - Resignation of CEO  
 
    Market Update  
 
    Amended Constitution  
 
    Appendix 3B  
 
    Results of Annual General Meeting  
 
    CEO AGM Presentation  
 
    Chairman's AGM Address  
 
    ViewnVivo installed for evaluation at Stanford University  
 
    First Sales of ViewnVivo in the Chinese Market  
 
    WA Investor Presentation - November 2017  
 
    Appendix 3Y - Peter Francis  
 
    Corrected Appendix 3Y  
 
    Appendix 3Y - Ian Griffiths  
 
    Appendix 3Y - Philip Currie  
 
    Appendix 3Y - Ian Mann  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    2017 Annual Report to Shareholders  
 
    Market Update on Convivo  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Change of Director's Interest Notices x3  
 
    Zeiss/Optiscan collaboration unveils Convivo  
 
    Change in substantial holding  
 
    Section 708A Cleansing Statement & Appendix 3B  
 
    Share Purchase Plan and Placement Completion  
 
    Appendix 4G and Corporate Governance Statement  
 
    2017 Annual Report to Shareholders  
 
    Investor Presentation - September 2017  
 
    Share Purchase Plan Results  
 
    Carl Zeiss Meditec to unveil in vivo Digital Biopsy Tool  
 
    Optiscan Appoints Exclusive China Distributor  
 
    An update from the Chairman  
 
    Despatch of Share Purchase Plan Documents to Shareholders  
 
    Notice under ASIC Class Order 09/425 - Share Purchase Plan  
 
    Preliminary Final Report - Appendix 4E  
 
    Share Placement and Underwritten Share Purchase Plan  
 
    Trading Halt  
 
    ViewnVivo Update  
 
    Appendix 3B  
 
    Market Update  
 
    Initial Director's Interest Notice  
 
    Director Appointment  
 
    Investor Presentation - July 2017  
 
    Optiscan Appoints Exclusive North American Distributor  
 
    Market Update  
 
    Change of Registered Office and Principal Place of Business  
 
    Market Update  
 
    Market Update  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Amended Appendix 4D  
 
    Market Update  
 
    Appendix 4D and Financial Statements - 31 Dec 2016  
 
    Resignation of Joint Company Secretary  
 
    Becoming a substantial holder  
 
    Amended Share Trading Policy  
 
    Change in substantial holding  
 
    Share Placement Completion and Appendix 3B  
 
    Cleansing Prospectus  
 
    Market Update - December 2016  
 
    Change of Director's Interest Notices (x4)  
 
    Appendix 3B  
 
    Prospectus - Share and Option Issues approved at AGM  
 
    Share Placement  
 
    Trading Halt  
 
    Company Secretary Appointment/Resignation  
 
    AGM voting- results  
 
    AGM- other than Chairman's address  
 
    AGM- Chairman's address  
 
    Pre-clinical research product launch  
 
    Receipt of R&D tax rebate incentive  
 
    Optiscan to hold investor presentation in Perth- Wed 30 Nov  
 
    AGM Notice of Meeting and Proxy Form  
 
    Response to ASX Price Query  
 
    Change of interests of substantial shareholder- form 604  
 
    Appendix 4G and Corporate Governance Statement  
 
    Annual Report  
 
    Optiscan Completes $2.16M Capital Raising  
 
    Completion of rights issue - shares issued  
 
    Preliminary Final Report- Appendix 4E  
 
    Appendix 3Y- increase in Director's interest  
 
    Update on cooperation with Carl Zeiss Meditec  
 
    Reinstatement to Official Quotation - 22 August 2016  
 
    Shares issued 19 August 2016 and request for reinstatement  
 
    Appendix 3B- shares issued 19 August 2016  
 
    Optiscan rights issue- shortfall notice  
 
    Rights issue- Confirmation of lodgement of documents  
 
    Optiscan announces new General Manager appointment  
 
    Rights issue- supplementary prospectus  
 
    Rights issue- letter to ineligible shareholders  
 
    Rights issue- letter to eligible shareholders  
 
    Rights issue- updated Appendix 3B  
 
    Rights issue- letter sent to option-holders  
 
    Chairman's letter- rights issue  
 
    2 for 9 rights issue - prospectus  
 
    Conversion of Director Loan to Equity  
 
    2 for 9 rights issue- notification of revised timing  
 
    New issue announcement  
 
    Announcement- capital raising  
 
    2 for 9 rights issue- appendix 3B  
 
    Change of Company Secretary and CFO  
 
    Update - Mid Year Accounts and Capital Raise  
 
    Optiscan Appendix 4D and Financial Statements (31 Dec 2015)  
 
    Update - 31 Dec 2015 Interim Report  
 
    CEO Appointment  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Board Changes  
 
    Funding Update and Ongoing Suspension  
 
    Final Director's Interest Notice  
 
    Director Appointment/Resignation  
 
    Optiscan Suspension and Funding Update  
 
    Optiscan Funding and Suspension Update  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Optiscan Receives R&D Tax Incentive, Loan Repaid  
 
    Appendix 3B  
 
    Final Director's Interest Notice  
 
    Board Changes and Funding Update  
 
    Initial Director's Interest Notice  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    CellLIVE Update  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Optiscan Corporate Governance Policy Statement 2015  
 
    Optiscan Appendix 4G  
 
    Full Year Statutory Accounts  
 
    Reinstatement to Official Quotation  
 
    Optiscan Zeiss Collaboration Update  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Final Director's Interest Notice  
 
    Board of Directors Change  
 
    Global Launch of CellLIVe in Hawaii, USA  
 
    Optiscan Appendix 4E and Financial Statements  
 
    Entitlements Issue Completed  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Letter to Shareholders from Angus Holt  
 
    Board Changes at Optiscan  
 
    Trading Halt  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Response to ASX Query  
 
    Notice of Shortfall for Entitlements Issue  
 
    Change of Directors Interest  
 
    Appendix to Form 604  
 
    Change in Substantial  
 
    Change of Interests Cover Letter  
 
    Reinstatement to Official Quotation  
 
    Notice under s708A  
 
    Appendix 3B  
 
    Non-Renounceable Issue  
 
    Funding and Update  
 
    Suspension From Official Quotation  
 
    Trading Halt  
 
    Half Yearly Report and Accounts  
 
    Response to ASX Price Query  
 
    Response to ASX Price Query  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Notice under S708A  
 
    Appendix 3B  
 
    Major Milestone Recognised  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Full Year Statutory Accounts  
 
    Market Introduction of CellLIVE by MR Solutions and Optiscan  
 
    Change in substantial holding  
 
    S708A Notice  
 
    Appendix 3B  
 
    NEW FUNDING FOR OPTISCAN  
 
    Trading Halt  
 
    Preliminary Final Report  
 
    Major Step in Zeiss Product Development  
 
    Section 708A Notice  
 
    Appendix 3B  
 
    New Funding Facility and Operations Update  
 
    Trading Halt  
 
    S708A Notice  
 
    Appendix 3B  
 
    S708A Notice  
 
    Appendix 3B  
 
    Optiscan in Clinical Study at St Vincents Sydney  
 
    Notice under S708A  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Publications Support Optiscan's New Product Directions  
 
    Change of Director's Interest Notice  
 
    New Global Supply Agreement  
 
    Appendix 3B Amended  
 
    Appendix 3B  
 
    Response to ASX Query  
 
    Appendix 3B  
 
    Appendix 3Y Angus Holt  
 
    Notice Under S708A  
 
    Appendix 3B  
 
    AGM Results  
 
    Chairman's Address to Shareholders  
 
    Notice under S708A  
 
    Appendix 3B  
 
    Notice under S 708A  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change in substantial holding from CIR  
 
    Change of Director's Interest Notice  
 
    Appendix 3B with Appendix  
 
    Appendix 3B  
 
    Annual Report to shareholders  
 
    Notice under Section 708A(5)(e) Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Preliminary Final Report  
 
    Half Yearly Report and Accounts  
 
    Section 708A (5) (e) Notice  
 
    Appendix 3B  
 
    Notice Under S708A(5)(e)  
 
    Appendix 3B  
 
    Response to ASX Diversity Policy  
 
    AGM Results  
 
    AGM Presentation  
 
    Notice under Section 708A(5)(e)  
 
    Appendix 3B  
 
    Investor Presentation  
 
    CEO Interview Available on Website  
 
    Annual Report to shareholders  
 
    Zeiss Milestones Actualised  
 
    Optiscan Presentation  
 
    Appendix 3B  
 
    Update, Capital Raise and Appendix 4E  
 
    Trading Halt  
 
    Trading Halt Request  
 
    Response to Appendix 3Y Query  
 
    Letter re Change of Director's Interest Notice  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice  
 
    Notice under Section 708A(5)(e)  
 
    Appendix 3B  
 
    Section 708A(5) Notice  
 
    Appendix 3B  
 
    Zeiss Neurosurgery Purchase Order  
 
    Section 708A notice  
 
    Appendix 3B  
 
    Appendix 3B  
 
    Shareholder Update June 2012  
 
    Notice under Section 708A(5)(e) Corporations Act  
 
    Appendix 3B  
 
    Appendix 3B - Conversion on Notes  
 
    Section 708A(5)(e) Notice  
 
    Appendix 3B  
 
    Notice under Section 708A (5)(e)  
 
    App 3B re Bergen Funding Facility  
 
    $2M Funding from Bergen Global Opportunity Fund, LP  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Change in substantial holding from CIR  
 
    Preliminary Final Report  
 
    Becoming a substantial holder  
 
    New US Patent for Optiscan  
 
    Appendix 3B  
 
    Strategic Review Process  
 
    Appointment of Strategic Advisors  
 
    Appendix 3B  
 
    Half Yearly Report and Accounts  
 
    Securities Trading Policy  
 
    Expansion of activities with Carl Zeiss Surgical  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Waiver from Listing Rules 10.13.3 and 10.13.5  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    March Quarter 2010 Update  
 
    Half Yearly Report and Accounts  
 
    Change of Director's Interest Notice  
 
    Becoming a substantial holder  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Management Changes at Optiscan  
 
    Results of Meeting  
 
    AGM Address 2009 - text and slides  
 
    Change of Director's Interest Notice x 3  
 
    Appendix 3B  
 
    Share Purchase Plan - Successful Completion  
 
    Notice of AGM and Proxy  
 
    Share Purchase Plan Documentation  
 
    Share Purchase Plan Notice Under ASIC Class Order 09/425  
 
    Share Purchase Plan Announcement  
 
    World First in Endoscopy  
 
    Response to an ASX Price Query  
 
    Annual Report to shareholders  
 
    Shareholder Newsletter  
 
    Preliminary Final Report  
 
    Optiscan Continues Collaboration With Carl Zeiss  
 
    New Hoya Agreements  
 
    Shareholder Update  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    New Contract with Carl Zeiss  
 
    Optiscan Terminates 2nd Generation Agreement with Hoya  
 
    Half Yearly Report and Accounts  
 
    Initial Director's Interest Notice  
 
    Director Appointment  
 
    Optiscan Announces Downsizing  
 
    Final Director's Interest Notice  
 
    Optiscan Scales down Board of Directors  
 
    Keith Daniel Retires from Optiscan board  
 
    Final Director's Interest Notice  
 
    Results of Meeting  
 
    AGM Address 2008  
 
    Optiscan commences new trial in robotic surgery  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Optiscan seeking to raise capital  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Notice of General Meeting Despatched today to Members  
 
    Initial Director's Interest Notice  
 
    New directors for Optiscan  
 
    S708A Notice re Placement  
 
    Appendix 3B  
 
    Optiscan Placement Raises $3M  
 
    Optiscan expands global coverage for FIVE 1 sales  
 
    Endomicroscopy Takes Centre Stage at DDW 2008  
 
    Optiscan hosts one day seminar  
 
    Multi Centre Trials in Europe Commence  
 
    Successful Milan Conference for Optiscan  
 
    Endomicroscopy Conference in Milan  
 
    Surgeons Can Now See What to Cut Thanks to Optiscan  
 
    Half Yearly Report and Accounts  
 
    Initial Director's Interest Notice  
 
    Issue of employee options  
 
    Optiscan Appoints New CEO as Director  
 
    Appendix 3Y G Latta  
 
    CEO Steps Down  
 
    App 3Y G Latta  
 
    App 3Y A Rogers  
 
    App 3Y G Latta  
 
    OPTISCAN APPOINTS NEW CEO  
 
    Results of Meeting  
 
    AGM Address 2007  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Optiscan initiates endometriosis clinical trial  
 
    Annual Report to shareholders  
 
    Pentax reaffirms commitment to endomicroscope sales growth  
 
    Preliminary Final Report  
 
    Optiscan CEO to step down by year end  
 
    Hoya bid for Pentax Successful  
 
    Soft sales for Optiscan in first half year  
 
    Appendix 3B Issue of employee options  
 
    Appendix 3B  
 
    Pentax UK announces new training centre for  
 
    Optiscan July 2007 investor presentation on website  
 
    Optiscan product sales 2006/07 $5.49M  
 
    Successful pilot trial indicates airways applications  
 
    Optiscan and Carl Zeiss Group Sign Collaboration Deal  
 
    New Endomicroscope Trial at Johns Hopkins Hospital  
 
    New Pentax Development Agreement for Optiscan  
 
    Appendix 3B: Exercise of Employee Options  
 
    Optiscans endomicroscopy features in UK awards  
 
    Pentax & Hoya Merger Update  
 
    Change in substantial holding - Ixohoxi  
 
    Endo-microscopy featured in State of the Art Lecture at DDW  
 
    Expanding role for endo-microscopy reported at DDW congress  
 
    Optiscan in US Roadshow  
 
    Award for Optiscan Founders  
 
    Change in substantial holding from CIR  
 
    Appendix 3B  
 
    Completion of Share Purchase Plan  
 
    Optiscan FIVE 1 progress confirms second commercialisation  
 
    Share Purchase Plan Extension of Closing Date  
 
    Congress presentations for Optiscans Endo-microscopy  
 
    Letter to Shareholders re Share Purchase Plan  
 
    Endo-microscopy training expanded  
 
    Share purchase plan to strengthen balance sheet  
 
    Half Yearly Report & Accounts  
 
    First half product sales and outlook for year  
 
    Pentax & Hoya merger signals growth for endoscope business